Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
2
Site 03
Newark, New Jersey, United States
Composite Endpoint of Alive and Free of Organ Failure at Day 28
Free of mechanical ventilation, free of renal replacement therapy and free of acute liver failure
Time frame: Day 28
Alive at Days 28 and 60
Time frame: Day 28 and Day 60
Alive, Out of ICU, at Day 28
Time frame: Day 28
Alive, Out of Hospital, at Days 28 and 60
Time frame: Day 28 and Day 60
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.